I do hope you are right and I am wrong. Too much distrust of martin and his greed. How about making Dean the CEO and saying goodbye to Martin?
He is a consultant. Hey Dean, what do you think we should do? How much do you really think Martin, with his ego, is going to listen to Dean? On paper, Dean is added to CMXI as a consultant. I doubt if he will have any influence at all. Martin has his plan for his raises and bonuses.
despite the thumbs down, it does not change the fact Tozer appears to have no role at CMXI other than some pumpers touting his name.
The hype is greatly overstating Tozer's role in cmxi. Martin will be the only star on this team.
I believe this applies to Martin and his cronies. That is why there are so many mouths to feed on the board.
Who can doubt that if eBay were a private company, Donahoe would be fired when the facts were disclosed to the owners? But sadly at many of our public companies, such as eBay, there is a lack of accountability, and transgressions by management are swept under the rug by crony boards. If middle management makes a costly error, they pay the price; if the CEO makes one, too often the “old boy” board covers it up and gives him a bonus. Less
I wrote and asked why there are more members on the board than there are out in the field selling product. No answer. I became very disheartened by every member of the board who I wrote. None seem to care about shareholder. They have a sweet gig as long as they stick together. raises, bonuses, free stock. Issue more shares whenever they need more money. Shareholders are getting milked.
Re: Update on #054
in response to Re: Update on #054 by TrickyRic
posted on Mar 05, 14 08:58AM Use the IP Check tool [?]
Yup and both received final rejections, thus the RCE's.
they can keep their paychecks rolling in by always promising but never delivering (story of pats career). oh well live and learn. anyone know of something in initial stage of something really good?
I agree. With our potential 3x is reasonable with martin at the helm. With someone more capable and interested in increasing shareholder value instead of increasing BoD value, we should be a 10x stock.
Wolf of wallstreet guys have no problem doing a 10 for 1 followed a few months later by another offering. Eventually getting back to same amount of shares outstanding except shareholders have been fleeced. No worries, does not affect $50,000 raise or bonus.
First class team running Cytmedix...GLTA!
Martin Rosendale, Chief Executive Officer
Mr. Rosendale joined Cytomedix, Inc. in March 2008 as COO and he was appointed Chief Executive Officer in July 2008. Prior to joining Cytomedix, Mr. Rosendale was Chief Executive Officer of Core Dynamics, Inc. where he managed their Israel based R&D program and initiated U.S. commercial operations for cryobiology and cell lyophilization technologies. Mr. Rosendale has more than 24 years of specialty medical experience. He has held leadership positions for the past 15 years with American Red Cross, SangStat, North American Vaccine and ZLB Bioplasma, in addition to serving on the boards of the Transplant Recipients International Organization and the American Red Cross Biomedical Services, San Jose Region. Mr. Rosendale earned a Bachelor of Science degree in Microbiology from California State University.
Edward L. Field, Chief Operating Officer
Ed Field has been employed at Cytomedix since February 2012. Aldagen since November 2004. Prior to joining Aldagen, Mr. Field was the President and Chief Executive Officer of Inologic, Inc., a private biopharmaceutical company, from 2002 to September 2004. Prior to joining Inologic, from 1999 to 2002, Ed was the President of Molecumetics, Ltd., a drug discovery and development subsidiary of Tredegar Corporation, until its merger with Therics, LLC, a regenerative medicine company. Ed received a Master of Business Administration degree from the University of Virginia's Darden School of Business Administration and a Bachelor of Science degree in Economics from Duke University.
Steven A. Shallcross, CPA, Executive Vice President, Chief Financial Officer, Secretary and Treasurer
Mr. Shallcross joined Cytomedix, Inc. in May 2013. Mr. Shallcross has over 25 years of international financial, business and strategic planning experience, primarily working with companies in the pharmaceutical and biotechnology industries. Prior to Cytomedix, Mr. Shallcross served as Executive Vice President and Chief Financial Officer of Empire Petroleum Partners, LLC, a motor fuel distributor. Previously, he served as Acting Chief Financial Officer for Sensors for Medicine and Science, Inc., a medical device company. Prior to that, he was Executive Vice President and Chief Financial Officer of Innocoll Holdings, Inc., a biopharmaceutical company specializing in the development and commercialization of collagen based products. Mr. Shallcross is a certified public accountant. He received a Bachelor’s degree in Accounting from the University of Illinois and an M.B.A. degree from the University of Chicago, Booth School of Business.
Peter A. Clausen, Ph.D., Vice President, Business DevelopmentDr. Clausen joined Cytomedix, Inc. in September 2008 after consulting tothe Company since May2008. Prior to joining Cytomedix, Dr. Clausen was a founding member and Vice President,Research and Development at Marligen Bioscience, a biotechnology company that develops,manufactures and markets innovative products for the life sciences market. Dr. Clausenis a seasoned biochemist with nearly 15 years experience in the biotechnology sector. Dr. Clausen completed his post-doctoral training in the Laboratory of Molecular Oncology at the National Cancer Institute where his research efforts focused in the areas of oncology, hematopoiesis, and gene therapy. Dr. Clausen earned a Bachelor of Science degree in Biochemistry from Beloit College and a Ph.D. in Biochemistry from Rush University.
Carelyn P FyllingCarelyn P. Fylling, R.N., M.S.N., C.W.S, C.L.N.C., Vice President, Professional Services
Ms. Fylling joined Cytomedix, Inc. in December 2001. Prior to Cytomedix,Ms. Fylling was recruited to start Curative Health Services, a biotechnology company specializing in the production of autologous platelet releasates for the management of chronic wounds. Since 1986, Ms. Fylling has been instrumental in developing point-of-care PRP systems, conducting clinical/outcome studies in chronic wounds, publishing and presenting on PRP, designing a national wound database, and training physicians and nurses in comprehensive wound management. She currently serves on the Board of Directors of the Association for the Advancement of Wound Care. She received her Bachelor of Science Degreein Nursing from North Park College, Chicago, IL and her Master of Science in Nursing from the University of California, San Francisco, Ca.
David JordenDavid Jorden, Executive Board Director & Investor Relations
Mr. Jorden joined Cytomedix, Inc. in September 2008. He brings to Cytomedix more than 20 years of public and private company investment experience. Prior to joining Cytomedix, Mr. Jorden was responsible for equity portfolio management at Morgan Stanley's Private Wealth Management group and previously served as CFO at Genometrix, Inc., a private genomics/life sciences company. Mr. Jorden serves on the Board of Opexa Therapeutics, Inc., PLx Pharma, Inc., and DLush, a San Diego based deluxe beverage company. Mr. Jorden earned a Master of Management from the Kellogg School of Management at Northwestern University and a BBA from the University of Texas at Austin. He holds both CFA and CPA designations.
Patrick P VanekPatrick P. Vanek, R.Ph., Vice President, OperationsPatrick Vanek joined Cytomedix, Inc. in July 2010. He brings to Cytomedix more than 30 years of diverse technical and managerial experience in pharmaceuticals and medical devices, specifically Formulation Design, Process Development, QA/QC and Supply Chain/Logistics. Prior to joining Cytomedix, Mr. Vanek spent 12 years at Otsuka America Pharmaceutical, Inc. where he rose through a number of managerial positions to become Vice President of Technical Operations. Prior to that, he held various development/technical management positions at KV Pharmaceutical Corp., Teva Pharmaceuticals USA, Wyeth Laboratories and McNeil Pharmaceutical. Mr. Vanek earned a B.S. in Pharmacy from the Philadelphia College of Pharmacy & Science and is a Registered Pharmacist.
Joe Del Guercio, Director
Mr. Del Guercio has served as a Director since February 8, 2012. Previously, he was an Observer for the Aldagen board of directors. Mr. Del Guercio joined CNF Investments in 2004 as a Managing Director. Prior to joining CNF, Mr. Del Guercio was a director with LPL Financial Services, a Boston and San Diego based independent broker dealer, with responsibility for strategic planning, new product development, and acquisitions. Prior to LPL, Mr. Del Guercio was with Robertson Stephens and Goldman Sachs, where he focused on mergers and acquisitions, private and public equity financings, and restructurings. Mr. Del Guercio serves on the boards of Vital Sensors, Verax Biomedical, Overture Technologies, Vision Chain, and DigitalBridge Communications. Mr. Del Guercio is also a board observer with Lipomics Technologies Inc., TerraGo Technologies and Innovative Biosensors, and is an advisory board member on a number of CNF’s fund investments. Mr. Del Guercio has an M.B.A. from Harvard Business School and a B.S. from Boston College.
Stephen N. Keith, M.D., Director
Stephen N. Keith, M.D., M.S.P.H. has served as a Director since September 19, 2008. Dr. Keith is the President and Chief Operating Officer of Panacea Pharmaceuticals, Inc.. From 2005 to 2006, Dr. Keith served as Senior Consultant at Biologics Consulting Group, LLC, a biopharmaceutical consulting company. From 2003 to 2005, he was Managing Director at Glocap Advisors LLC, a division of Glocap Funding LLC, an investment banking firm. Dr. Keith has held a range of senior management positions in the pharmaceutical and biotechnology industries, including President and Chief Operating Officer at Antex Biologics Inc., and Vice President, Marketing and Sales at North American Vaccine, Inc., Dr. Keith also serves as Chairman of the Board of Directors of NanoVec, Inc., an early-stage biopharmaceutical company. Dr. Keith holds an undergraduate degree magna cum laude from Amherst College in Massachusetts (1973), a degree in medicine from University of Illinois, College of Medicine, (1977) and a Master of Science in Public Health degree from the University of California, Los Angeles (1982). He is a licensed physician in the states of California and Maryland. Dr. Keith is a Fellow of the Academy of Pediatrics and a Diplomate of the American Board of Pediatrics.
Richard Kent, M.D., Director
Dr. Kent has served as a Director since February 8, 2012. Previously, he was a member of the Aldagen board of directors from March 2010- February 2012. Since 2008, he has been a Venture Partner with Intersouth Partners, a venture capital firm. Dr. Kent served as the President and Chief Executive Officer of Serenex, Inc., a biotechnology company focused on oncology, from 2002 until its sale to Pfizer in April 2008. Prior to joining Serenex, he served as President and Chief Executive Officer of Ardent Pharmaceuticals, Inc. and held senior executive positions at GlaxoSmithKline, Glaxo Wellcome, and Burroughs Wellcome. Dr. Kent has served as a director of Inspire Pharmaceuticals, Inc., a publicly traded biotechnology company, since June 2004. Dr. Kent received his undergraduate degree from the University of California, Berkely and his M.D. from the University of California, San Diego. He is board certified in both internal medicine and cardiology.
Lyle A. Hohnke, Ph.D., Director
Dr. Hohnke has served as a Director since February 8, 2012. Previously, he served as Aldagen's Chief Executive Officer since 2011 and as a Director on Aldagen's Board from August 2008- February 2012. He has been a partner of Tullis Dickerson, a healthcare-focused venture capital fund, since 1994. Dr. Hohnke holds Ph.D. and M.A. degrees from the University of Oregon and was a postdoctoral fellow at the UCLA School of Medicine. He holds an M.B.A. from the Hartford Graduate Institute at Rensselaer Polytechnic Institute and a B.A. degree from Western Michigan University.
Mark T. McLoughlin, Director
Mark T. McLoughlin has served as a Director since June 7, 2004. Mr. McLoughlin currently serves as a Senior Vice President for VWR International, a global distributor of laboratory supplies, equipment and services to the pharma, biotech, industrial and clinical laboratory. In this capacity, he has responsibility for the sourcing and marketing functions for North America. Prior to joining VWR International, he was Senior Vice President, Chief Marketing Officer for Cardinal Health based in Rolle, Switzerland. Prior to joining Cardinal, he was vice president of commercial operations for Norwood Abbey Ltd., an Australian-based medical technology company. Earlier, he was President of North American operations for Ion Beam Application, Inc., a Belgium-based global medical technology company. His executive career experience also includes Mallinckrodt, as well as positions with other healthcare companies.
C. Eric Winzer, Director
C. Eric Winzer has served as Director since January 30, 2009. Mr. Winzer currently serves as Executive Vice President and Chief Financial Officer of Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX). Prior to joining Avalon, Mr. Winzer was with Life Technologies Corporation (Nasdaq: LIFE), formerly Invitrogen Corporation, a provider of life science technologies for disease research and drug discovery, from 2000 to 2006, where he served as Senior VP and Chief Financial Officer, Executive Sponsor for Life's ERP implementation and VP, Finance. From 1986 to 2000, Mr. Winzer held various positions of increasing responsibilities at Life Technologies, Inc., including Chief Financial Officer, Secretary and Treasurer. From 1980 until 1986 he held various financial positions at Genex Corporation. Mr. Winzer received his B.A. in Economics and Business Administration from McDaniel College and an M.B.A. from Mount Saint Mary's University
Sure are a lot of folk running CMXI with those 8 salesmen. Enough for one executive per salesman. What do they do all day?
be forewarned. the cheerleaders on agoracom will tell you all the great things about nunchi and signet. nonetheless, when facebook, google, Microsoft make huge purchases or acquisitions, they aint buying edig. the experts in the industry no looking at edig. freddy falk with has been pat nonely are being paid to dance a dance, sing a song. will they really ever do something? 8 pennies per ticket to watch.
If you are in the mood to write, please join me. Letters to any and all of the Board. Ask why so many members on the board? Or why they don't buy shares of CMXI on the open market? Or what do they consider "fiduciary responsibility to shareholders" entails? So many questions for this silent group.
Martin gave himself a raise and bonus prematurely. Before he had earned it. Partnership did not happen, trials got halted, proper CMS approval did not happen. Too many members on the Board. Executives of company not purchasing stock. Not having skin in the game. It has become everyone milking the shareholder. Voice your displeasure and remind them of their fiduciary responsibilities to shareholders. This is not a private club. Martin's raise needs to be rescinded.
Still, too many mouths to feed for a one trick pony of a company. Perhaps they are listening to the outcry from shareholders demanding they take their fiduciary responsibilities serious or face litigation.
C. Eric Winzer, Director
Lyle A. Hohnke, Ph.D., Director
Richard Kent, M.D., Director
Stephen N. Keith, M.D., Director
Joe Del Guercio, Director
James Benson, Principal Director
David Jorden, Executive Chairman
209 Perry Parkway
All of you make money by being on the board of directors. Why you no buy shares at these historically low prices
basically for the 9 months ending 12-31-13 our income was @ $1.8 million and that the largest licensee paid 13% of that, several others paid 11% of that and that every other licensee paid less than 10% of the total.
Donny, I think they finally woke up and realize they have been duped. Page 9 revealed how little they are getting for licensing fees. A big chunk has to go to Handal. Then they are realizing that every quarter, they are told the same thing about Nunchi and Signet. They are developing it, testing it, almost there, interested parties are looking at it, ... It looks like everyone is realizing nonething coming from Nunchi. And with so little coming from licensing, there cant be much upside for shareprice. sad ending to fred falk country club membership subsidization
when cms decision was made, by making a big splash. Get the word out. Would have helped his sales staff and his shareholders. But he already had his raise and bonus so why bother. So the short interest went up to 1 million in January yet out of no where we have 1.2 million shares traded...somehow there is probably a covering going on....it will be interesting to see if it disappears in the next report.
They need to get a real CEO ...Marty is too ho hum....we need someone that can promote this....when they got the ruling from CMS, Marty should have been on a major road show to get the word out.
the upside is all the shorts will eventually have to cover. If the financing comes in around 45 cents, then we should see a lot of buying to help hold the support? I would buy more if we go back into the 30 cent range.